Skip to main content

Advertisement

SpringerLink
Log in

The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

In patients with luminal-type breast cancer (positive for ER and/or PgR), a complete consensus on the threshold indication for a combination of chemotherapy and endocrine therapy has not been achieved, especially for patients with HER2-negative luminal type (HNLT). Girdin, an actin-binding Akt substrate, plays a crucial role in the migration of cancer cells. This study examined the expression of Girdin in relation to clinicopathological features and other immunohistochemical markers (HER2, Ki-67), especially in patients with HNLT breast cancer.

Methods

One hundred one breast cancer patients who underwent surgery were evaluated. Immunohistochemical staining was performed for Girdin and other biomarkers, such as ER, PgR, HER2, and Ki-67.

Results

Positive expression of Girdin was observed in 26 patients. The expression of Girdin was significantly associated with the incidence of lymph node metastases (p = 0.001). Among the other examined biomarkers, positive expression of Ki-67 also showed a significant association with the incidence of lymph node metastases (p = 0.04). In the HNLT breast cancer patients (n = 73), the 5-year recurrence-free survival rate was significantly lower (57 %) in patients with positive expression of both Girdin and Ki-67 than the rate in other patients (92 %) (p = 0.002).

Conclusion

This study demonstrated that the expression of Girdin in invasive breast cancer is strongly associated with lymph node metastasis. The expression status of Girdin and Ki-67 can be a useful biomarker in stratifying patients with HNLT breast cancer into those with high risk of recurrence and the need for additional chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212–20.

    Article  PubMed  CAS  Google Scholar 

  3. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 2005;16(11):1723–39.

    Article  PubMed  CAS  Google Scholar 

  4. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Can. 2002;2(7):489–501.

    Article  CAS  Google Scholar 

  5. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol CB. 1999;9(11):601–4.

    Article  PubMed  CAS  Google Scholar 

  6. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Fork head transcription factor AFX by protein kinase B. Nature. 1999;398(6728):630–4.

    Article  PubMed  CAS  Google Scholar 

  7. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 2001;21(6):2203–12.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K, et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell. 2005;9(3):389–402.

    Article  PubMed  CAS  Google Scholar 

  9. Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. Can Res. 2008;68(5):1310–8.

    Article  CAS  Google Scholar 

  10. Liu C, Zhang Y, Xu H, Zhang R, Li H, Lu P, et al. Girdin protein: a new potential distant metastasis predictor of breast cancer. Med Oncol. 2012;29(3):1554–60.

    Article  PubMed  CAS  Google Scholar 

  11. Ling Y, Jiang P, Cui SP, Ren YL, Zhu SN, Yang JP, et al. Clinical implications for girdin protein expression in breast cancer. Can Inv. 2011;29(6):405–10.

    Article  Google Scholar 

  12. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Can Inst. 2011;103(22):1656–64.

    Article  CAS  Google Scholar 

  13. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Can Inst. 2009;101(10):736–50.

    Article  CAS  Google Scholar 

  14. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155–68.

    PubMed  CAS  Google Scholar 

  15. Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol. 2009;62(1):6–12.

    Article  PubMed  CAS  Google Scholar 

  16. Kroger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Can Res. 2006;12(1):159–68.

    Article  CAS  Google Scholar 

  17. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Can Res Treat. 2008;107(3):309–30.

    Article  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Kazumi Nishimae, Nobuyuki Tsunoda, Yukihiro Yokoyama, Toshio Kokuryo & Masato Nagino

  2. Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Akari Iwakoshi & Masahide Takahashi

Authors
  1. Kazumi Nishimae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuyuki Tsunoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukihiro Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshio Kokuryo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akari Iwakoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masahide Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masato Nagino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuyuki Tsunoda.

About this article

Cite this article

Nishimae, K., Tsunoda, N., Yokoyama, Y. et al. The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer. Breast Cancer 22, 445–451 (2015). https://doi.org/10.1007/s12282-013-0501-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-013-0501-3

Keywords

Search

Navigation